Pharmaceutical News

RSS

Teva Pharmaceutical granted FDA approval for Flumazenil injection

Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.

13 Oct 2004

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

MedImmune has announced that data from a preclinical study for its lead vaccine candidate to prevent respiratory syncytial virus (RSV) and parainfluenza virus type-3 (PIV-3) has shown a protective immune response against both viruses in animals.

13 Oct 2004

California issues alert and warning about flu vaccine price gouging

California State Attorney General Bill Lockyer has urged consumers and pharmacists to provide his office information about price gouging by flu vaccine suppliers and warned he will take enforcement action against those who exploit the supply shortage by charging unconscionable prices.

13 Oct 2004

FDA and MHRA to cooperate efforts to address manufacturing concerns related Chiron's influenza vaccine

The FDA and the U.K's MHRA have announced their intent to continue in a cooperative effort to address the manufacturing quality concerns related to the production of Chiron's influenza vaccine, Fluvirin, at the company's Liverpool facility.

13 Oct 2004

CDC and Aventis Pasteur plan to allocate influenza vaccine

The Centers for Disease Control and Prevention (CDC) and Aventis Pasteur announced today the first phase of the plan to allocate influenza vaccine in response to the recently announced loss of half of the nation’s expected flu vaccine supply for the 2004-2005 season.

12 Oct 2004

New survey reveals continued drug price disparities across the New York State

New York State Attorney General Eliot Spitzer has announced that his office's drug price website has been expanded to include pharmacies within every county in New York State.

11 Oct 2004

Pharmacists respond to unprecedented demand for the flu vaccine in the wake of the current shortage

Pharmacists are responding to unprecedented demand for the flu vaccine in the wake of the current shortage. The pharmacist is on the front line in addressing consumers’ questions and concerns about the availability of the vaccine and in helping Americans understand the CDC’s priorities for administration of the immunization.

10 Oct 2004

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.

8 Oct 2004

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Following the announcement that the nation is facing a flu vaccine shortage this year, the Generic Pharmaceutical Association (GPhA) renewed its call for the Food and Drug Administration (FDA) and Congress to move forward to accelerate the approval of affordable generic biopharmaceuticals and vaccines.

8 Oct 2004

Aspirin might well be considered the top utility player in the medicine cabinet

This cheap over-the-counter drug can be used not only for fever, pain and arthritis, but to prevent heart attack, stroke or angina. It also may reduce the risk of colorectal cancer. Yet aspirin also has side effects worth considering, and its very accessibility may hamper its use.

8 Oct 2004

Vioxx: an unequal partnership between safety and efficacy

Last week’s dramatic withdrawal of the COX-2 inhibitor rofecoxib (Vioxx) is discussed in this week’s lead editorial in THE LANCET, which comments that more vigilant drug licensing is vital to prevent the endangering of patients’ health.

7 Oct 2004

Canadian Rheumatology Association issues statement on Vioxx alternatives

The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week.

7 Oct 2004

EMEA statement following withdrawal of Vioxx (rofecoxib)

EU regulators met with the marketing authorisation holder of Vioxx (rofecoxib), Merck Sharp & Dohme, on 4-5 October 2004 at the informal meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) held in Scheveningen, The Netherlands.

6 Oct 2004

Ireland's Department of Health has resolved outstanding concerns over the availability of flu vaccines

The Ireland's Department of Health has resolved outstanding concerns over the availability of flu vaccines and has secured commitments from new suppliers that will fully meet Ireland’s needs this winter.

5 Oct 2004

U.S. healthcare industry reaction to the withdrawal of Vioxx from the world-wide market

NDCHealth has announced U.S. healthcare industry reaction to the Sept. 30 announcement by Merck & Co. that it was withdrawing its anti-arthritic medication Vioxx from the world-wide market.

5 Oct 2004

U.S. Department of Health and Human Services responds to loss of Chiron flu vaccine

Clearly, the loss of the Chiron flu vaccine poses a serious challenge to our vaccine supply for the upcoming flu season. Chiron was to produce between 46-48 million doses of influenza vaccine for the United States.

5 Oct 2004

RiboNovix secures license to novel anti-infective discovery technology from Wayne State University

New biotechnology company, RiboNovix, Inc., is addressing the worsening problem of antibiotic-resistant bacteria by developing new anti-infectives that are less susceptible to drug resistance.

5 Oct 2004

Natural alternatives to osteoarthritis drug

The recall of Vioxx should come as a major sign of the need to look for safer alternatives for osteoarthritis treatment, according to the Director of the Australian Centre for complementary Medicine Education and Research (ACCMER), Professor Stephen Myers.

5 Oct 2004

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is expected to begin immediately.

5 Oct 2004

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

A trial of beta-interferon-1a in inclusion-body myositis (IBM) has failed to find benefit from the drug in this disease. Beta-interferons counteract some of the activities of the immune system, which some experts believe is misguided in IBM.

5 Oct 2004

Pharmaceutical News

Teva Pharmaceutical granted FDA approval for Flumazenil injection

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

California issues alert and warning about flu vaccine price gouging

FDA and MHRA to cooperate efforts to address manufacturing concerns related Chiron's influenza vaccine

CDC and Aventis Pasteur plan to allocate influenza vaccine

New survey reveals continued drug price disparities across the New York State

Pharmacists respond to unprecedented demand for the flu vaccine in the wake of the current shortage

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Aspirin might well be considered the top utility player in the medicine cabinet

Vioxx: an unequal partnership between safety and efficacy

Canadian Rheumatology Association issues statement on Vioxx alternatives

EMEA statement following withdrawal of Vioxx (rofecoxib)

Ireland's Department of Health has resolved outstanding concerns over the availability of flu vaccines

U.S. healthcare industry reaction to the withdrawal of Vioxx from the world-wide market

U.S. Department of Health and Human Services responds to loss of Chiron flu vaccine

RiboNovix secures license to novel anti-infective discovery technology from Wayne State University

Natural alternatives to osteoarthritis drug

Teva Pharmaceuticals granted final approval for Ribavirin capsules

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News